Endoxifen Concentration Is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2023.1285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Beomki Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Tamoxifen, Antineoplastic Agents, Hormonal. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
The metabolism of tamoxifen is influenced by various cytochrome p450 enzymes, including CYP2D6 and CYP2C19, leading to variations in the levels of endoxifen, even with the same tamoxifen dose. However, the clinical significance of endoxifen for the prognosis of breast cancer patients remains controversial. This study aimed to elucidate the relevance of endoxifen level to recurrence-free survival censored with tamoxifen discontinuation (RFSt), representing the RFS for tamoxifen itself, of breast cancer patients and determine a suitable cutoff for prognostication.Materials and Methods The study included 478 breast cancer patients. Tamoxifen and its metabolites, including endoxifen, were measured using liquid chromatography-tandem mass spectrometry. An optimal cutoff was determined with maximally selected rank statistics. Survival analysis and Cox regression were conducted based on this cutoff.
Results
An endoxifen level of 21.00 ng/mL was the optimal cutoff for prognostication. Survival analysis revealed a statistically significant difference in RFSt between the low endoxifen group (≤ 21.00 ng/mL) and the high endoxifen group (> 21.00 ng/mL) (log-rank test, p=0.032). The 10-year probability of RFSt was 83.2% (95% confidence interval [CI], 77.0 to 89.9) and 88.3% (95% CI, 83.3 to 93.5) in the low and high endoxifen groups, respectively. Multivariable Cox proportional hazards regression indicated endoxifen concentration as a significant factor associated with prognosis.
Conclusion
Endoxifen could serve as a marker for appropriate tamoxifen treatment with a cutoff of 21.00 ng/mL. Based on this cutoff, therapeutic drug monitoring would benefit patients displaying suboptimal endoxifen concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Förderung
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
Zitieren
APA
Lee, B., Nam, S. J., Kim, S. W., Yu, J., Chae, B. J., Lee, S. K., Ryu, J. M., Lee, J. E., & Lee, S. Y. (2025). Endoxifen Concentration Is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.1285
Vancouver
Lee B, Nam SJ, Kim SW, Yu J, Chae BJ, Lee SK, et al. Endoxifen Concentration Is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients. Cancer Research and Treatment. 2025. doi:10.4143/crt.2023.1285
BibTeX
@article{Lee2025,
author = {Lee, Beomki and Nam, Seok Jin and Kim, Seok Won and Yu, Jonghan and Chae, Byung-Joo and Lee, Se Kyung and Ryu, Jai Min and Lee, Jeong Eon and Lee, Soo-Youn},
title = {Endoxifen Concentration Is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2023.1285}
}
EUVIMED